{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Endocrine+Disorders&page=104", "query": { "condition": "Endocrine Disorders", "page": 104 }, "page_size": 10 }, "pagination": { "page": 104, "page_size": 10, "total_count": 13471, "total_pages": 1348, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Endocrine+Disorders&page=105&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Endocrine+Disorders&page=103&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-12T08:41:11.429Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02443155", "title": "A Clinical Proof-of-principle Trial in Adult Subjects With Newly Diagnosed Type 1 Diabetes Mellitus Investigating the Effect of NNC0114-0006 and Liraglutide on Preservation of Beta-cell Function", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diabetes", "Diabetes Mellitus, Type 1" ], "interventions": [ { "name": "NNC0114-0006", "type": "DRUG" }, { "name": "liraglutide", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novo Nordisk A/S", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "18 Years to 45 Years" }, "enrollment_count": 308, "start_date": "2015-11-10", "completion_date": "2019-02-27", "has_results": true, "last_update_posted_date": "2021-04-09", "last_synced_at": "2026-11-12T08:41:11.429Z", "location_count": 13, "location_summary": "La Jolla, California • Northridge, California • Aurora, Colorado + 10 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Northridge", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Miami", "state": "Florida" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02443155" }, { "nct_id": "NCT06507878", "title": "Global Real World Data in Patients With Advanced Thyroid Cancer on Standard of Care and Specialized Interventions- Registry of Oncologic Outcomes With Testing and Treatment.", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Thyroid Cancer" ], "interventions": [], "intervention_types": [], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 459, "start_date": "2024-12-05", "completion_date": "2034-07-01", "has_results": false, "last_update_posted_date": "2026-09-18", "last_synced_at": "2026-11-12T08:41:11.429Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06507878" }, { "nct_id": "NCT07033585", "title": "Generic Drugs (Dapagliflozin and Saxagliptin) Treat Type 2 Diabetes Patients With Controlled Cancers", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Type 2 Diabetes" ], "interventions": [ { "name": "Farxiga® (dapagliflozin) + Onglyza® (saxagliptin) + Metformin Oral Mix Treat type 2 diabetes", "type": "DRUG" }, { "name": "China Import (dapagliflozin) + China Import (saxagliptin) + Metformin Oral Mix Treat type 2 diabetes", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Han Xu, M.D., Ph.D., FAPCR, Medical Director,, IRB Chair", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "24 Years", "maximum_age": "64 Years", "sex": "ALL", "summary": "24 Years to 64 Years" }, "enrollment_count": 600, "start_date": "2026-06-15", "completion_date": "2026-11-28", "has_results": false, "last_update_posted_date": "2026-08-27", "last_synced_at": "2026-11-12T08:41:11.429Z", "location_count": 1, "location_summary": "Rockville, Maryland", "locations": [ { "city": "Rockville", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT07033585" }, { "nct_id": "NCT01151215", "title": "Study of Anastrozole +/- AZD8931 in Postmenopausal Women With Endocrine Therapy Naive Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Neoplasms", "Breast Neoplasms", "Breast Cancer" ], "interventions": [ { "name": "AZD8931", "type": "DRUG" }, { "name": "anastrozole", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 482, "start_date": "2010-06", "completion_date": "2013-01", "has_results": true, "last_update_posted_date": "2014-07-25", "last_synced_at": "2026-11-12T08:41:11.429Z", "location_count": 1, "location_summary": "Lake Success, New York", "locations": [ { "city": "Lake Success", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01151215" }, { "nct_id": "NCT03607617", "title": "ASCEND: ApproacheS to CHC ImplEmeNtation of SDH Data Collection and Action", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Diabetes Mellitus" ], "interventions": [ { "name": "SDH Tool", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Kaiser Permanente", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 31, "start_date": "2018-09-03", "completion_date": "2023-07-31", "has_results": true, "last_update_posted_date": "2026-01-22", "last_synced_at": "2026-11-12T08:41:11.429Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT03607617" }, { "nct_id": "NCT06673017", "title": "PTM-101 in Pancreatic Ductal Adenocarcinoma (PDAC)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pancreatic Ductal Adenocarcinoma", "Borderline Resectable Pancreatic Adenocarcinoma", "Locally Advanced Pancreatic Adenocarcinoma", "Pancreatic Cancer" ], "interventions": [ { "name": "PTM-101", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "PanTher Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 26, "start_date": "2025-04-14", "completion_date": "2028-06", "has_results": false, "last_update_posted_date": "2026-10-08", "last_synced_at": "2026-11-12T08:41:11.429Z", "location_count": 8, "location_summary": "Newport Beach, California • Miami, Florida • Detroit, Michigan + 4 more", "locations": [ { "city": "Newport Beach", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Lake Success", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06673017" }, { "nct_id": "NCT03938740", "title": "Comparison of Different Insulin Dosing Algorithms Using Hepatic Directed Vesicle-Insulin Lispro and Insulin Degludec", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diabetes Mellitus, Type 1" ], "interventions": [ { "name": "HDV-Insulin Lispro and Insulin Degludec (-40%)", "type": "DRUG" }, { "name": "HDV-Insulin Lispro and Insulin Degludec (-10%)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Diasome Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 61, "start_date": "2019-03-18", "completion_date": "2020-03-18", "has_results": false, "last_update_posted_date": "2020-04-02", "last_synced_at": "2026-11-12T08:41:11.429Z", "location_count": 7, "location_summary": "San Mateo, California • Aurora, Colorado • Atlanta, Georgia + 4 more", "locations": [ { "city": "San Mateo", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Roswell", "state": "Georgia" }, { "city": "Morehead City", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03938740" }, { "nct_id": "NCT06535789", "title": "Inhaled Insulin vs Rapid-acting Injections for Post-meal Glucose Control in Women With Gestational Diabetes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Diabetes, Gestational", "Pregnancy Complications", "Glucose Metabolism Disorders", "Glucose Intolerance During Pregnancy" ], "interventions": [ { "name": "Inhaled Technosphere Insulin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Jaeb Center for Health Research", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "FEMALE", "summary": "18 Years to 45 Years · Female only" }, "enrollment_count": 30, "start_date": "2025-06-02", "completion_date": "2026-09-05", "has_results": false, "last_update_posted_date": "2026-10-19", "last_synced_at": "2026-11-12T08:41:11.429Z", "location_count": 5, "location_summary": "Santa Barbara, California • Aurora, Colorado • New York, New York + 2 more", "locations": [ { "city": "Santa Barbara", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "New York", "state": "New York" }, { "city": "Portland", "state": "Oregon" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT06535789" }, { "nct_id": "NCT03099174", "title": "This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasms", "Breast Neoplasms" ], "interventions": [ { "name": "Xentuzumab", "type": "DRUG" }, { "name": "Abemaciclib", "type": "DRUG" }, { "name": "Letrozole", "type": "DRUG" }, { "name": "Anastrozole", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 133, "start_date": "2017-05-04", "completion_date": "2024-05-16", "has_results": true, "last_update_posted_date": "2025-06-24", "last_synced_at": "2026-11-12T08:41:11.429Z", "location_count": 6, "location_summary": "Santa Monica, California • New Haven, Connecticut • Miami, Florida + 3 more", "locations": [ { "city": "Santa Monica", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Miami", "state": "Florida" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "Las Vegas", "state": "Nevada" } ], "official_url": "https://clinicaltrials.gov/study/NCT03099174" }, { "nct_id": "NCT07148713", "title": "Pilot of Continuous Glucose Monitor-Augmented Food Is Medicine", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Nutrition", "Type 2 Diabetes", "T2DM", "T2DM (Type 2 Diabetes Mellitus)", "Diabetes Education", "Diabetes Type 2", "Diabetes Mellitis" ], "interventions": [ { "name": "CGM-Augmented FIM", "type": "BEHAVIORAL" }, { "name": "FIM only", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "University of North Carolina, Chapel Hill", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2025-09-19", "completion_date": "2026-12", "has_results": false, "last_update_posted_date": "2026-11-02", "last_synced_at": "2026-11-12T08:41:11.429Z", "location_count": 1, "location_summary": "Chapel Hill, North Carolina", "locations": [ { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT07148713" } ] }